{
  "id": "CD015536.PUB2",
  "draft": "Is entecavir effective and safe for children and adults with chronic hepatitis B compared to no treatment or a placebo?\n\nWe looked at the benefits and harms of entecavir for children and adults with chronic hepatitis B. We wanted to know if entecavir is better than no treatment or a placebo in reducing serious health problems and improving quality of life.\n\n- Due to very low-certainty evidence, we are very uncertain whether entecavir reduces serious harmful effects compared to no treatment or a placebo. It is also unclear if it affects the risk of death, mainly because no deaths occurred in any of the entecavir and no treatment or placebo groups in the studies.\n- The review found no information about how entecavir affects a person's quality of life, and more research is needed to understand the true benefits and harms of this treatment.\n\nWhat is chronic hepatitis B and why is it a problem?\nChronic hepatitis B is a major public health concern worldwide. It is a liver infection caused by the hepatitis B virus (a type of virus that attacks the liver) that can lead to serious health problems, including liver damage, liver cancer, and death. Entecavir is one of the antiviral therapy options (a type of treatment that fights viruses) used to treat chronic hepatitis B.\n\nWhat did we want to find out?\nWe wanted to evaluate the benefits and harms of entecavir compared to no treatment or placebo (a dummy treatment) in children and adults with chronic hepatitis B. We aimed to find out whether entecavir is effective in reducing the risk of serious health problems, such as death from any cause and serious harmful effects, and improving quality of life.\n\nHow did we conduct this review?\nWe searched for studies comparing entecavir with no treatment or placebo in people with chronic hepatitis B, summarized their results, and rated our confidence in the evidence.\n\nWhat did we find?\nWe found 22 studies that involved 2940 people with chronic hepatitis B. The studies were conducted over a period of 5 weeks to 228 weeks. We are very uncertain if entecavir reduces serious harmful effects compared to no treatment or a placebo. It is unclear if entecavir has an effect on death from any cause, because no deaths were reported in either the entecavir or the placebo/no treatment groups in the studies. There is a lack of data on quality of life.\n\nWhat are the limitations of the evidence?\nOur confidence in the evidence is limited for a few reasons:\n- In some studies, participants may have known which treatment they were getting, which could have influenced the results.\n- The studies were also very small, which makes it hard to be certain about the results.\n\nHow up-to-date is the evidence?\nThe evidence is up to date to July 2024.",
  "metrics": [
    {
      "linguistic_evaluation": {
        "words": {
          "value": 491,
          "rating": "within_limit",
          "direction": null,
          "feedback": null
        },
        "sentences": {
          "value": 25,
          "rating": "info",
          "direction": null,
          "feedback": null
        },
        "words_per_sentence": {
          "value": 19.64,
          "rating": "P25",
          "direction": "lower_better",
          "feedback": null
        },
        "passive_voice": {
          "value": 12,
          "rating": "P50",
          "direction": "lower_better",
          "feedback": null
        },
        "active_voice": {
          "value": 37,
          "rating": "P50",
          "direction": "higher_better",
          "feedback": null
        },
        "pronouns": {
          "value": 33,
          "rating": "P75",
          "direction": "higher_better",
          "feedback": null
        },
        "nominalization": {
          "value": 22,
          "rating": "P90",
          "direction": "lower_better",
          "feedback": "Deviates from typical PLS patterns. Consider reducing from 22.0 to <13.0 (median)"
        },
        "nouns": {
          "value": 135,
          "rating": "P75",
          "direction": "lower_better",
          "feedback": null
        },
        "flesch_reading_ease": {
          "value": 56.29591934826885,
          "rating": "P75",
          "direction": "higher_better",
          "feedback": null
        },
        "flesch_kincaid_grade": {
          "value": 10.286300610997966,
          "rating": "P25",
          "direction": "lower_better",
          "feedback": null
        },
        "automated_readability_index": {
          "value": 9.407535641547863,
          "rating": "P25",
          "direction": "lower_better",
          "feedback": null
        },
        "coleman_liau_index": {
          "value": 8.931323828920569,
          "rating": "P25",
          "direction": "lower_better",
          "feedback": null
        },
        "gunning_fog_index": {
          "value": 14.943576374745419,
          "rating": "P25",
          "direction": "lower_better",
          "feedback": null
        },
        "lix": {
          "value": 49.17156822810591,
          "rating": "P25",
          "direction": "lower_better",
          "feedback": null
        },
        "rix": {
          "value": 5.8,
          "rating": "P25",
          "direction": "lower_better",
          "feedback": null
        },
        "smog_index": {
          "value": 11.831760866327848,
          "rating": "P50",
          "direction": "lower_better",
          "feedback": null
        },
        "dale_chall_readability": {
          "value": 7.052168439918534,
          "rating": "P25",
          "direction": "lower_better",
          "feedback": null
        },
        "complex_words_dc": {
          "value": 189,
          "rating": "P75",
          "direction": "lower_better",
          "feedback": null
        },
        "complex_words": {
          "value": 87,
          "rating": "P75",
          "direction": "lower_better",
          "feedback": null
        },
        "long_words": {
          "value": 145,
          "rating": "P75",
          "direction": "lower_better",
          "feedback": null
        }
      },
      "word_count_status": {
        "word_count": 491,
        "limit": 850,
        "status": "within_limit",
        "message": "Word count: 491 ✓ WITHIN LIMIT (≤850 words)"
      },
      "summary": {
        "P25_count": 8,
        "P50_count": 3,
        "P75_count": 6,
        "P90_count": 1,
        "P10_count": 0,
        "BEYOND_P90_count": 0,
        "BELOW_P10_count": 0,
        "total_evaluated": 18,
        "P25_percentage": 44.44444444444444,
        "P50_percentage": 16.666666666666664,
        "P75_percentage": 33.33333333333333,
        "P90_percentage": 5.555555555555555,
        "P10_percentage": 0,
        "BEYOND_P90_percentage": 0,
        "BELOW_P10_percentage": 0,
        "best_quartile_rate": 77.77777777777779,
        "overall_assessment": "HIGHLY CONFORMS TO TYPICAL PLS PATTERNS"
      }
    }
  ],
  "evaluation": [
    {
      "grade": "NOT_APPROVED",
      "feedback": "This is a strong draft that passes all critical checks for accuracy and completeness. However, a few key improvements are needed to enhance clarity for the reader, particularly in the key messages.\n\nHere are the top 3 improvements needed:\n\n1. **Simplify the first key message.** This bullet point is 45 words long and combines two separate findings, which can be difficult for readers to absorb.\n   - **Original text:** \"- Due to very low-certainty evidence, we are very uncertain whether entecavir reduces serious harmful effects compared to no treatment or a placebo. It is also unclear if it affects the risk of death, mainly because no deaths occurred in any of the entecavir and no treatment or placebo groups in the studies.\"\n   - **Suggested rewrite:** Break this into two distinct bullet points:\n     \"- We are very uncertain if entecavir reduces serious harmful effects compared to no treatment or a placebo. The evidence is of very low certainty.\n     - We don't know if entecavir affects the risk of death, because no deaths occurred in any group in the studies we found.\"\n\n2. **Use more direct verbs instead of noun phrases.** The draft sometimes uses noun-heavy phrases that make the text less direct. This is reflected in the high 'nominalization' score from the analysis.\n   - **Original text:** \"There is a lack of data on quality of life.\"\n   - **Suggested rewrite:** Use a direct verb to state what the studies did (or didn't do):\n     \"The studies did not provide data on quality of life.\"\n\n3. **Simplify wordy phrases.** Some phrases can be made more concise to improve readability, as recommended in the style guide.\n   - **Original text:** \"The studies were conducted over a period of 5 weeks to 228 weeks.\"\n   - **Suggested rewrite:** Use a more direct and common phrase:\n     \"The studies followed people for 5 to 228 weeks.\"",
      "pls_evaluation_summary": "The linguistic analysis shows the draft highly conforms to typical PLS patterns, with 78% of metrics falling in the best quartile for readability. Sentence length and vocabulary are excellent. However, the analysis identified a significant deviation in the use of nominalizations (noun-form verbs), which scored in the 90th percentile, suggesting the text could be made more direct by using more active verbs."
    }
  ]
}